Logo image of TCON

TRACON PHARMACEUTICALS INC (TCON) Stock Price, Quote, News and Overview

NASDAQ:TCON - Nasdaq - US89237H3084 - Common Stock - Currency: USD

1.43  -0.02 (-1.38%)

After market: 1.08 -0.35 (-24.48%)

TCON Quote, Performance and Key Statistics

TRACON PHARMACEUTICALS INC

NASDAQ:TCON (6/27/2024, 7:53:15 PM)

After market: 1.08 -0.35 (-24.48%)

1.43

-0.02 (-1.38%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.75
52 Week Low0.66
Market Cap3.83M
Shares2.68M
Float2.62M
Yearly DividendN/A
Dividend YieldN/A
PE0.16
Fwd PEN/A
Earnings (Next)08-12 2024-08-12/amc
IPO01-30 2015-01-30


TCON short term performance overview.The bars show the price performance of TCON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 -60 -80

TCON long term performance overview.The bars show the price performance of TCON in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TCON is 1.43 USD. In the past month the price decreased by -5.3%. In the past year, price decreased by -75.43%.

TRACON PHARMACEUTICALS INC / TCON Daily stock chart

TCON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About TCON

Company Profile

TCON logo image TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.

Company Info

TRACON PHARMACEUTICALS INC

4350 La Jolla Village Drive, Suite 800

San Diego CALIFORNIA 92122 US

CEO: Charles P. Theuer

Employees: 18

Company Website: https://www.traconpharma.com/

Phone: 18585500780

TRACON PHARMACEUTICALS INC / TCON FAQ

What is the stock price of TRACON PHARMACEUTICALS INC today?

The current stock price of TCON is 1.43 USD. The price decreased by -1.38% in the last trading session.


What is the ticker symbol for TRACON PHARMACEUTICALS INC stock?

The exchange symbol of TRACON PHARMACEUTICALS INC is TCON and it is listed on the Nasdaq exchange.


On which exchange is TCON stock listed?

TCON stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TRACON PHARMACEUTICALS INC stock?

9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43. Check the TRACON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TRACON PHARMACEUTICALS INC worth?

TRACON PHARMACEUTICALS INC (TCON) has a market capitalization of 3.83M USD. This makes TCON a Nano Cap stock.


How many employees does TRACON PHARMACEUTICALS INC have?

TRACON PHARMACEUTICALS INC (TCON) currently has 18 employees.


What are the support and resistance levels for TRACON PHARMACEUTICALS INC (TCON) stock?

TRACON PHARMACEUTICALS INC (TCON) has a support level at 1.23 and a resistance level at 1.5. Check the full technical report for a detailed analysis of TCON support and resistance levels.


Is TRACON PHARMACEUTICALS INC (TCON) expected to grow?

The Revenue of TRACON PHARMACEUTICALS INC (TCON) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TCON EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TRACON PHARMACEUTICALS INC (TCON) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TRACON PHARMACEUTICALS INC (TCON) stock pay dividends?

TCON does not pay a dividend.


When does TRACON PHARMACEUTICALS INC (TCON) report earnings?

TRACON PHARMACEUTICALS INC (TCON) will report earnings on 2024-08-12, after the market close.


What is the Price/Earnings (PE) ratio of TRACON PHARMACEUTICALS INC (TCON)?

The PE ratio for TRACON PHARMACEUTICALS INC (TCON) is 0.16. This is based on the reported non-GAAP earnings per share of 9.07 and the current share price of 1.43 USD. Check the full fundamental report for a full analysis of the valuation metrics for TCON.


TCON Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TCON Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TCON. The financial health of TCON is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TCON Financial Highlights

Over the last trailing twelve months TCON reported a non-GAAP Earnings per Share(EPS) of 9.07. The EPS increased by 808.59% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.39%
ROA 18.69%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-269.44%
Sales Q2Q%N/A
EPS 1Y (TTM)808.59%
Revenue 1Y (TTM)N/A

TCON Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to TCON. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -142.4% and a revenue growth -100% for TCON


Ownership
Inst Owners9.71%
Ins Owners214.98%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target31.11 (2075.52%)
EPS Next Y-142.4%
Revenue Next Year-100%